Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Oncol
Hoofdauteurs: Hu, Chen-Yu, Xu, Xiang-Ming, Hong, Bo, Wu, Zhi-Gang, Qian, Yun, Weng, Tian-Hao, Liu, Yi-Zhi, Tang, Tao-Ming, Wang, Ming-Hai, Yao, Hang-Ping
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2019
Onderwerpen:
Oncology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906148/
https://ncbi.nlm.nih.gov/pubmed/31867280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01377
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items